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Abstract
Background. Around 40% of people with bipolar disorder (BD) are non-adherent to medication
leading to relapse, hospitalisation and increased suicide risk. Limited progress in addressing
non-adherence may be partly attributable to insufficient understanding of the modifiable deter-
minants of adherence that require targeting in interventions. We synthesised the modifiable
determinants of adherence in BD and map them to the theoretical domains framework (TDF).
Method. We searched CINAHL, Cochrane Library, Embase, LILACS, Medline, PsychINFO
and PubMed until February 2020. We included studies reporting modifiable determinants
of adherence in BD. Two reviewers independently screened studies, assessed quality, extracted
modifiable determinants and mapped them to TDF.
Results. We included 57 studies involving 32 894 participants. Determinants reported by
patients spanned 11 of the 14 TDF domains compared to six domains represented by
clinician/researcher. The TDF domains most commonly represented (% and example) in studies
were: ‘Environmental context and resources’ (63%, e.g. experiencing side effects), ‘Beliefs about
consequences’ (63%, e.g. beliefs about medication effects), ‘Knowledge’ (40%, e.g. knowledge
about disorder), ‘Social influences’ (33%, e.g. support from family/clinicians), ‘Memory, attention
and decision processes’ (33%, e.g. forgetfulness), ‘Emotion’ (21%, e.g. fear of addiction) and
‘Intentions’ (21%, e.g. wanting alternative treatment). ‘Intentions’, ‘Memory, attention and
decision processes’ and ‘Emotion’ domains were only reported by patients but not clinicians.
Conclusions. Clinicians may be underappreciating the full range of modifiable determinants
of adherence and thus not providing adherence support reflective of patients’ needs. Reporting
of modifiable determinants in behavioural terms facilitates developing theory-based interven-
tions to address non-adherence in BD.
Background
Bipolar disorder (BD) is generally a recurrent, lifelong mental health condition with a high risk
of disability and excess mortality (Grande, Berk, Birmaher, & Vieta, 2016; Vazquez, Holtzman,
Lolich, Ketter, & Baldessarini, 2015). The worldwide lifetime prevalence of the BD is estimated
at 1% (Rowland & Marwaha, 2018). BD usually requires long-term medication but an estimated
40% of people are non-adherent to medication leading to relapse, functional impairment
and suicidality (Gonzalez-Pinto et al., 2006; Lingam & Scott, 2002; Strakowski et al., 1998;
Velligan et al., 2009). Medication non-adherence increases the probability of hospitalisation
by at least five times (Scott & Pope, 2002).
Efforts to improve medication adherence have had marginal effects (Easthall, Taylor, &
Bhattacharya, 2019; Nieuwlaat et al., 2014). This may be due to limited understanding of
the modifiable determinants of medication adherence and existing support focussing on a
narrow range of adherence determinants. We define modifiable determinants as ‘any determi-
nants (barriers or facilitators) of medication adherence that can be modified by the patient,
carer, or the prescriber within a short timeframe (days or weeks) to improve adherence’.
We define a barrier as ‘a circumstance that prevents the patient from taking their medication
as prescribed’, whereas a facilitator is ‘a circumstance that makes the process easy or easier’
(Oxford English dictionary online: Oxford university press, 2017). Some evidence syntheses
report determinants of adherence to mental health treatment but they do not clearly distin-
guish between those that are modifiable, such as knowledge regarding how to take medication
and non-modifiable such as age and gender. Such distinction is vital to allow adherence
interventions to target modifiable determinants.
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Furthermore, any differences between the perspective of clini-
cians and patients on determinants of medication adherence
require exploration. Clinicians are the treatment experts but
patients are the experts of their lived experience. Their goals, pri-
orities and knowledge of the situation may differ. Thus, clinicians
and patients may see the determinants of medication adherence
differently (Devine, Edwards, & Feldman, 2018; Velligan et al.,
2009). Exploring such differences will help design adherence
support based on the patient’s needs.
A recent systematic review by Garcia et al. provides an over-
view of barriers to medication adherence in BD and schizophrenia
(Garcia et al., 2016). However, the study limited on determinants
of adherence to antipsychotics (one group of medication to man-
age BD). Other common medications for BD are known as mood
stabilisers which includes lithium. The omission of adherence
determinants to lithium and other mood stabilisers is significant
since lithium is recognised as the first-line gold standard long-
term therapy in BD [Grunze et al., 2013; National Institute of
Health and Care Excellence (NICE), 2014]. It is also noteworthy
that the challenges to adhere to lithium may be different as lith-
ium is a narrow therapeutic index drug and thus require a regular
blood test, some dietary restrictions and has significant interac-
tions with other medications [National Institute of Health and
Care Excellence (NICE), 2014]. Furthermore, the review does
not delineate modifiable from non-modifiable determinants
which lack specific behaviour change techniques (BCTs)
(Michie, Johnston, Francis, & Hardeman, 2008).
Additionally, the lack of behavioural theory underpinning the
evidence synthesis in medication adherence in BD is evident.
Thus, a systematic review of modifiable determinants of all treat-
ment option in BD underpinned by theoretical framework is
needed. Further details regarding the rationale for this systematic
review are provided in the published protocol (Prajapati et al.,
2019).
This systematic review aimed to identify modifiable determi-
nants of medication adherence in BD reported in the literature
and map them to the theoretical domains framework (TDF).
This study is a part of the Collaborative Medication Adherence
in Bipolar disorder (C-MAB) project funded by Health Education
England/National Institute for Health Research UK. The C-MAB
project aims to develop a medication adherence tool for people
with BD. The project advisory board includes stakeholders,
patients, carers, clinicians, health psychologist and experts in
behavioural medicine.
Method
The study was registered with PROSPERO, registration number:
CRD42018096306.
The protocol with detailed methods for this systematic review
is published elsewhere (Prajapati et al., 2019), and a summary of
the methods is provided below.
We searched CINAHL, Cochrane Library, Embase, LILACS,
Medline, PsychINFO and PubMed from database inception to
October 2018 using the search terms ‘Treatment Adherence and
Compliance’, ‘Bipolar Disorder’ and ‘Psychotropic Drugs’. We
updated the search in February 2020. The detailed search strategy
is available in online Supplementary file.
We included primary, qualitative and quantitative studies pub-
lished in the English language and studies explicitly reporting
modifiable determinants of medication adherence in BD in adults.
We excluded reviews, intervention studies to improve adherence,
case reports, clinical guidelines or general disease management
articles, studies involving short-term treatment of acute agitation
or treatment other than medication such as psychotherapy.
Two reviewers (AP, DB, FS, GM, JW and SS) independently
screened the study abstracts and full-texts and carried out the
quality assessment. Disagreements were resolved through discus-
sion and referral to a third reviewer for arbitration if necessary. A
range of quality assessment tools (Center for Evidence Based
Management, 2014; Critical Appraisal Skills Programme, 2018;
National Institute of Health, 2014) was used according to the
study designs (Frambach, van der Vleuten, & Durning, 2013).
We used Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) (Moher, Liberati, Tetzlaff, Altman, &
The PRISMA Group, 2009) checklist for data extraction and
reporting. The completed PRISMA checklist is available in online
Supplementary file 2.
Underpinning theoretical framework
We used framework analysis with the TDF as an a priori frame-
work, to map modifiable determinants of medication adherence
to their relevant TDF domain. The use of a theoretical framework
provides a broad lens through which to capture the literature
identified modifiable determinants. The TDF is a comprehensive
framework capturing 33 theories and 84 theoretical constructs
related to behaviour change (Atkins et al., 2017). Atkins et al.
report the definition of each TDF domain and construct within
each domain (Atkins et al., 2017). TDF was developed as a con-
sensus framework by experts in health service research and behav-
iour science (Michie et al., 2005). The TDF offers the additional
advantage that each of its 14 domains is coupled with BCTs
(Michie et al., 2008). Thus, mapping modifiable determinants
of adherence to the TDF offers a significant utility for interven-
tion development.
Two independent reviewers (AP, AD, DB and SS), with experi-
ence in using the TDF, extracted modifiable determinants and
coded them to the TDF domains using Nvivo 12 (QSR
International Pty Ltd, 2018). For example, the extracted text ‘lack
of awareness that medication needed to be taken regularly led to
non-adherence’ in the study was coded to the TDF domain
‘Knowledge’. In addition to the 14 TDF domains, we also created
another domain called ‘Others’ for any modifiable determinant
not suitable to map to those 14 domains. Agreement between two
reviewers in mapping modifiable determinants to the same TDF
domain was calculated in SPSS version 25 using Cohen’s kappa.
We grouped the modifiable determinants into overarching
themes (Gale, Heath, Cameron, Rashid, & Redwood, 2013). We
also coded whether the modifiable determinants were barriers
or facilitators and whether it was reported by patients, clinicians,
carers or any other third parties.
Results
From the 2517 studies retrieved, we included 57, comprising 32
894 patients and clinicians. Figure 1 provides the screening pro-
cess, number of retrieved studies, number of studies included
and excluded during title screening, abstract screening and full
text screening as well as the reasons for exclusion. The primary
reasons for exclusion at full-text screening were failure to report
modifiable determinants or reporting an intervention to address
adherence.
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Study characteristics
Summary characteristics such as study design, participant details
and, country in which the included study was conducted are
presented in Table 1. Fifty studies explored determinants from
the perspective of patients and two (Vieta et al., 2012; Younas,
Bradley, Holmes, Sud, & Maidment, 2016) from clinicians’
perspective. Three studies included both patient and clinician
perspectives (Baldessarini, Perry, & Pike, 2008; Maczka,
Siwek, Skalski, Grabski, & Dudek, 2010; Pope & Scott, 2003).
Further two studies were from the researcher’s perspective
(Gianfrancesco, Sajatovic, Tafesse, & Wang, 2009; Greene et al.,
2018). However, none of the studies included carers. Most of
the included studies collected data via surveys or interviews.
The majority (79%) of the studies were conducted in the USA
and Europe. A majority of the studies (64%) were focused purely
on BD. Of the 57 included studies, 33% (Arvilommi et al., 2014;
Baldessarini et al., 2008; Bauer et al., 2013; Fleck, Corey,
Strakowski, & Keck, 2005; Grover, Ghosh, Sarkar, Chakrabarti,
& Avasthi, 2014; Hajda et al., 2015; Johnson et al., 2007;
Jonsdottir et al., 2013; Jose, Bhaduri, & Mathew, 2003; Manwani
et al., 2007; Nagesh, Kishore, & Raveesh, 2016; Pope & Scott,
2003; Ralat, Depp, & Bernal, 2018; Roe, Goldblatt, Baloush-
Klienman, Swarbrick, & Davidson, 2009; Scott & Pope, 2002;
Stentzel et al., 2018; Vieta et al., 2012) explicitly focused on
exploring barriers to adherence. Table 2 describes the quality of
the included studies. The majority (65%) of the studies was
of moderate quality, 19% were of high quality and 16% were of
low quality.
Reported modifiable determinants of medication adherence
We extracted 290 modifiable determinants, which were grouped
into 33 themes and mapped to 11 TDF domains. Inter-rater reli-
ability for mapping the modifiable determinants to the TDF
domains was 76% (Cohen’s kappa 0.71), indicating substantial
agreement between the reviewers (Landis & Koch, 1977).
Cohen’s kappa was calculated using SPSS 25.0 (IBM
Corporation, 2017). Examples of the modifiable determinants,
themes of determinants and TDF domains to which they were
mapped are reported in Table 3.
Some facilitators were reported as the opposite of barriers. For
example, ‘cost of medication’ was identified as a barrier in the
‘Environmental context and resources’ domain, for which ‘medi-
cation being free of charge’ represented the corresponding facili-
tator. In other cases, facilitators were occasionally worded as
BCTs. For example, forgetfulness represented a barrier in the
‘memory, attention, and decision processes’ domain, for which
the corresponding facilitators were reminders and formulating
routines; these were classified in the BCT category of ‘prompts
and cues’ which may successfully modify behaviour by addressing
determinants in this TDF domain (Johnston et al., 2020).
The TDF domains represented in the greatest number of stud-
ies were ‘Environmental context and resources’ (63% of studies)
and ‘Beliefs about consequences’ (63% of studies). Experience of
side effects (49% of studies) and the nature of the medication,
e.g. tablet, injection and dose frequency (22% of studies) were
the main determinants mapped to the former; acting as barriers
when unacceptable and facilitators when acceptable to patients.
Fig. 1. PRISMA flow diagram.
PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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Table 1. Summary of included studies
Study details Study design Study included Study aims
No. of




Cross-sectional survey BD, schizophrenia,
depression
Assessment of associated factors
that might influence compliance
409 Ireland Not reported
Arvilommi et al. (2014) Structured Clinical
Interviews
BD only Explored barriers of adherence: to
investigate reasons were for
treatment discontinuation
168 Finland Not reported
Averous, Charbonnier,
Lagouanelle-Simeoni,
Dany, and Prosperi (2018)
Face to face interview BD only To explore associations between
illness perceptions and adherence
38 France Not reported
Baldessarini et al. (2008) Survey BD only Explored barriers of adherence: risk









BD only To identify and describe correlates
of medication adherence
1052 USA 49.5%




BD only Explored barriers of adherence: to
investigate regularity in the daily
mood stabiliser dosage taken by
patient and factors associated with
irregularity
206 Germany Not reported
Belzeaux et al. (2013) Cross-sectional survey and
interviews
BD only To explore adherence behaviour
and characterise the
sociodemographic and clinical
factors associated with adherence








To examine the extent of compliance
and non-compliance and examine
the factors that affect compliance.
564 Qatar 41.8%
Clatworthy et al. (2007) Semi-structured interviews BD only To explore in-depth beliefs about
BD and its treatment that are
associated with adherence to
medication prescribed for BD
16 UK 8 reported
non-adherence in the
past and 5 reported
current non-adherence
Clatworthy et al. (2009) Questionnaire survey BD only The utility of the necessity
concerns framework for
understanding patient attitudes




Semi-structured interviews BD only To determine the factors affecting
treatment compliance
78 Turkey 42.3%
Copeland et al. (2008) Cross-sectional survey BD only To determine the association of
insight and adherence
435 USA 27% had poor
adherence based on
missed dose and 46%
had poor adherence
based on Moriskey
Correard et al. (2017) Cross-sectional
observational
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Darling et al. (2008) Survey/interview BD only The influence of family and health
stress, level of coping and internal
health locus of control upon the
life contentment of adherent and
non-adherent individuals
100 USA Not applicable as
purposive sampling to
include 50 adherent and
50 non-adherent
patients
De Las, Penate, and Sanz
(2014)
Survey Bipolar, depression and
dysthymia
To identify potential modelling
factors influencing adherence
145 Spain 46.2%




To examine the role of perceived
health control variables in
psychiatric patients’ adherence to
prescribed treatment.




adherence and 28.2% a
low adherence
Deegan (2005) Interviews BD, schizophrenia,
major depression, and
others
To understand how people with
psychiatric disorders demonstrate
the capacity for resilience in the
ways they use or do not use
psychiatric medications
29 USA Not reported
Fleck et al. (2005) Interviews BD only Explored barriers of adherence: to
examine rates, self-perceived
reasons and attitudes associated
with non-adherence
50 USA 45% African American






BD only The study investigated
monotherapy v. polypharmacy









To compare differences in
medication adherence and
discontinuation between those
who initiated a long acting
injection and those who changed
from one oral antipsychotic
monotherapy to another
11 344 USA 61.1% in LAIs group and
78.5% in oral group
Greenhouse, Meyer, and
Johnson (2000)
Survey BD only This report hypothesised that
acceptance coping would correlate
positively, and denial coping would
correlate inversely with adherence




Grover et al. (2014) Survey and semi
structured interview with
the patient and spouse/
partner
BD only Explored barriers of adherence: to
evaluate the prevalence of sexual
dysfunction in patients with BD
receiving lithium and to study the
correlates of sexual dysfunction
100 India Varied (used BARS,
MAQ) 84% took the
prescribed doses of
medications
Hajda et al. (2015) Survey BD only Explored barriers of adherence: to
determine the relationship
between current adherence,
medication discontinuing in the
past and self-stigma
33 Czech Republic Nineteen (57.6%)
patients discontinued
medication
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Table 1. (Continued.)
Study details Study design Study included Study aims
No. of




Survey BD only Explored barriers of adherence: to





Hou, Cleak, and Peveler
(2010)
Survey BD only To investigate the impact of
treatment and illness beliefs on
medication adherence
35 UK 54.3% (probably
non-adherent)
Inder, Lacey, and Crowe
(2019)
Interviews BD only Analysis of medication adherence 36 New Zealand NA
Johnson et al. (2007) Survey BD only Explored barriers of adherence: to
investigate factors associated with
nonadherence and to assess the
effect of patient preference on
hypothetical medications





Jonsdottir et al. (2013) Interviews Bipolar and
schizophrenia
Explored barriers of adherence: to
investigate potential risk factors for
medication nonadherence
255 Norway 13% Nonadherent, 31%
partial adherent
Jose et al. (2003) Survey BD only Explored barriers of adherence: to
identify the reason for
non-compliance
96 India Not applicable
(purposive sampling)
Kamaradova et al. (2016) Survey Bipolar, schizophrenia,
depression, anxiety
disorder and others
Explored barriers of adherence: to
examine associations between
self-stigma and adherence to
treatment and discontinuation of
medication in patients from
various diagnostic groups




Keck et al. (1996) Cohort study – patients
evaluated at admission and
followed up at 6 months
BD only To identify clinical factors associated
with maintenance antipsychotic
treatment in patients with BD
77 USA Varied, 41–68%
Keck, McElroy, Strakowski,
Bourne, and West (1997)
Interviews BD only To assess patients’ compliance
with pharmacotherapy
140 USA 51%
Kraemer et al. (2013) Observational study BD only To assess the duration of time on
different mood stabilising
medications and retention rates in
standard clinical care
761 Germany 28.4%
Kutzelnigg et al. (2014) Observational study BD only To determine factors associated
with better compliance and to
assess compliance between
patients stabilised on olanzapine







were observed in 67% of
patients at baseline,
increasing to 80% in
study completers
Maczka et al. (2010) Survey Psychiatrists and
patients with BD
An analysis and comparison of
patients’ and psychiatrists’ beliefs
regarding the most important
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Manwani et al. (2007) Structured Interviews BD only Explored barriers of adherence: to
examine patterns and reasons of
non-adherence
115 USA 17.5% in non-substance
users, 34.5% in
substance users





To gain a better understanding of















Explored barriers of adherence: to
assess the level of patients’
adherence to psychotropic
medications and to explore factors
associated with non-adherence to
medication
156 India Adherence rate varied
from low adherence
(24.4%) through
medium (34%) to high
adherence (41.7%)
among participants




To explore non adherence with












To examine concurrent and
predictive associations between
provider support and adherence,
access to care and health related
quality of life
433 USA Not reported
Pope and Scott (2003) Survey Patients with BD and
their treating clinicians
Explored barriers of adherence:
likely reasons for non-adherence
identified by patients, the most
common concerns of adherent and










Ralat et al. (2018) Focus group BD only Explored barriers of adherence: to
identify patients’ perspectives on
the reasons for nonadherence to
psychiatric medication
22 Puerto Rico 68% of participants
reported nonadherence
during the week of
recruitment
Roe et al. (2009) Semi-structured interviews Bipolar and
schizophrenia
Explored barriers of adherence: to
explore why and how people with a
serious mental illness choose to
stop taking prescribed medication
7 Israel Not applicable
Rosa et al. (2007) Survey BD only To determine plasma and red
blood cell lithium concentrations in
bipolar patients at the same time
as estimating attitudes and
knowledge about lithium
treatment in adherence scales
106 Brazil 33.06% based on MARS
>7 14.4% based on
plasma lithium
Rosenblat et al. (2018) Survey Bipolar depression and
Major depressive
disorder
Explore factors that impact
treatment decisions
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Table 1. (Continued.)
Study details Study design Study included Study aims
No. of




Interview and self-report BD only Evaluated factors related to
adherence
184 USA 38.6%
Sajatovic et al. (2009) Interviews BD only This cross-sectional analysis
examined clinical and subjective
variables in relation to adherence
140 USA 19.3%




BD only This mixed-method analysis
evaluated factors related to
adherence among 20 poorly
adherent community mental
health clinic patients with BD
20 USA Not applicable
Scott and Pope (2002) Structured clinical
interviews
BD (n = 78) and major
depressive disorder (n
= 20)
Explored barriers of adherence: to
explore the prevalence and
predictors of nonadherence with
mood stabilisers
98 UK Variable (47% had been
non-adherent within
last 2 years)
Sharma et al. (2012) Survey BD, schizophrenia and
depression










Explored barriers of adherence: to
examine potential determinants of
non-adherence for patients with
severe mental disorders
127 Germany 54% of the participants
reported some kind of
non-adherence
Teter et al. (2011) Interviews BD only The study examined the impact of
substance use disorder history with
regards to medication-taking
behaviours and attitudes




Semi-structured interviews BD only To characterise the patients’
perceptions and to give
information that can help identify
some of the factors involved in the
treatment nonadherence
50 Mexico Not reported
Vieta et al. (2012) Survey Psychiatrist treating
bipolar patients
Explored barriers of adherence: to
canvas the opinions of
psychiatrists treating patients with
BD and ascertain their perceptions







that 57% of their
patients were partially
or non-adherent
Weiss et al. (1998) Structured interviews Coexisting BD and
substance use disorder
The study examined the pattern of
medication compliance and
reasons for non-compliance
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Beliefs about the likely positive/negative outcomes arising from
adhering (36% of studies) and a belief that the medication is
not needed (25% of studies) were the main determinants mapped
to the latter.
Other TDF domains (and corresponding themes of determi-
nants) reported in 20% or more studies, among all studies, were
‘Knowledge’ (whether the patient had sufficient knowledge about
BD or its treatment); ‘Social influences’ (support or opposition
from family, friends, relatives, clinicians regarding adherence);
‘Emotion’ (fear of addiction to or side effect from medication);
‘Memory, attention, and decision process’ (forgetfulness/careless-
ness with medication taking) and ‘Intentions’ (denial of illness or
need for treatment).
Modifiable determinants were most frequently reported in the
context of barriers rather than facilitators. However, unlike most
other TDF domains, for ‘social influences’, facilitators and bar-
riers were reported with similar frequency. This trend was also
observed for ‘Social/Professional Role and identity’. Modifiable
determinants related to ‘Goals’ and ‘Skills’ were infrequently
reported. No determinants were mapped to the TDF domains
of ‘Optimism’, ‘Reinforcement’ and ‘Behavioural regulation’.
Determinants from the perspectives of patients and clinicians
Figure 2 illustrates the TDF domains reported in patient studies
compared to clinician studies. ‘Beliefs about consequences’ and
‘Environmental context and resources’ were the two most fre-
quently reported TDF domains in both patient studies as well
as clinicians studies. There were, however, noticeable differences
in the range and nature of determinants reported by patients
relative to clinicians. Determinants reported by clinicians were
mapped to only six TDF domains compared to 11 TDF domains
covered by patient studies. Only patient studies reported determi-
nants which were mapped to the TDF domains ‘Intention’,
‘Memory, attention and decision process’ and ‘Emotion’. These
domains included determinants such as denial of the illness or
need for treatment, forgetfulness/carelessness and fear of addic-
tion to or side effect of medication respectively (see Table 3 for
more details).
Furthermore, ‘Goals’ and ‘Skills’ domains were reported in
patient studies, albeit infrequently. An example of determinants
in these two domains includes different priorities over medication
taking and provision of training to manage BD, as shown in
Table 3.
Clinicians reported modifiable determinants of adherence
themed around lack of knowledge about medication, shared
decision making, belief in self and perceived control, belief that
medication is not needed, belief about positive or negative effects
of medication, side effects, ineffective medication and irregular
routine.
Two studies reported determinants from the researcher
perspective (Gianfrancesco et al., 2009; Greene et al., 2018)
namely medication formulations (such as tablets and injections)
and the number of medications, both of which were mapped to
‘Environmental context and resources’ domain.
Discussion
Synthesis of the literature through the theoretical lens of the TDF
has enabled us to identify that negative emotions evoked by medi-
cation taking and intentional non-adherence make a notable con-
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existing interventions on practical barriers to adherence
(MacDonald, 2017; Torres-Robles et al., 2018), clinicians should
additionally address negative emotions and lack of intentions.
In common with previous evidence syntheses, modifiable
determinants were primarily barriers to adherence (Garcia et al.,
2016; Velligan et al., 2009) with few reported facilitators. This
may be an artefact of the included studies focussing on the chal-
lenges experienced by patients, rather than seeking to explore
potential solutions. This hypothesis is supported by a third of
the included studies explicitly seeking only barriers to medication
adherence. For the few studies exploring facilitators, determinants
that are not the opposite of barriers, such as wanting to keep the
mood stable and not wanting to be hospitalised, have also been
reported (Clatworthy, Parham, Horne, Bowskill, & Rank, 2007;
Darling, Olmstead, Lund, & Fairclough, 2008). A strength of
the present review is that we did not restrict the search to only
adherence barriers; thus, we have identified a gap in the literature.
Current adherence interventions in BD focus mostly on educa-
tion regarding medication and BD, cognitive therapy to address
negative attitudes and beliefs, family therapy to encourage social
support and technology to address forgetfulness (MacDonald,
2017; Torres-Robles et al., 2018). Furthermore, adherence support
in the UK focusses on shared decision making regarding the
choice of medication, side effects profile of medication, cost of
medication and exploring patients beliefs [Care Quality
Commission (CQC), 2018; National Institute of Healthand Care
Excellence (NICE), 2009]. However, in this study, we found a
broad range of other modifiable determinants that may be affect-
ing medication adherence. This study provides clinicians with a
comprehensive list of modifiable determinants of medication
adherence, some of which are underappreciated by clinicians
and unaddressed by existing adherence interventions.
Advantages of mapping modifiable determinants to the TDF
Mapping determinants to the TDF allows them to be linked to
BCTs. Thus, this study provides a foundation for developing a
complex adherence intervention tailored to patients’ needs
based on their predominant determinants of adherence. The
most frequently reported TDF domains of ‘Beliefs about conse-
quences’ and ‘Environmental context and resources’ indicate
that working with the patient’s belief system, medication accept-
ability and tolerability are vital to support medication adherence.
However, other modifiable determinants, particularly in
‘Intentions’, ‘Memory, attention and decision process’ and
‘Emotion’ domains, presented in this study may be equally or
more relevant to individual patients. Thus, identifying the modi-
fiable determinants most pertinent to an individual patient is
critical to providing patient-centred adherence support.
The most frequently reported domain ‘Environmental context
and resources’ was primarily related to medication characteristics
such as side effects, treatment regime, medication effectiveness or
Table 2. Quality of included studies
High quality (n = 11) Moderate quality (n = 37) Low quality (n = 9)
Belzeaux et al. (2013)
Clatworthy et al. (2009)
Copeland et al. (2008)
Deegan (2005)
De Las et al. (2016)
Hou et al. (2010)
Kamaradova et al. (2016)
Sajatovic et al. (2006)
Sajatovic et al. (2009)
Sajatovic et al. (2011)
Vargas-Huicochea et al. (2014)
Agyapong et al. (2009)
Arvilommi et al. (2014)
Averous et al. (2018)
Baldessarini et al. (2008)
Bates et al. (2010)
Bauer et al. (2013)
Clatworthy et al. (2007)
Col et al. (2014)
Darling et al. (2008)
De Las et al. (2014)
Fleck et al. (2005)
Gianfrancesco et al. (2009)
Greene et al. (2018)
Grover et al. (2014)
Hibdye et al. (2015)
Inder et al. (2019)
Johnson et al. (2007)
Jonsdottir et al. (2013)
Keck et al. (1996)
Kraemer et al. (2013)
Kutzelnigg et al. (2014)
Maczka et al. (2010)
Manwani et al. (2007)
Morselli and Elgie (2003)
Nagesh et al. (2016)
Novick et al. (2017)
Pope and Scott (2003)
Ralat et al. (2018)
Roe et al. (2009)
Rosenblat et al. (2018)
Scott and Pope (2002)
Stentzel et al. (2018)
Teter et al. (2011)
Vieta et al. (2012)
Weiss et al. (1998)
Younas et al. (2016)
Zeber et al. (2008)
Bener et al. (2013)
Correard et al. (2017)
Greenhouse et al. (2000)
Hajda et al. (2015)
Jose et al. (2003)
Keck et al. (1997)
Perron et al. (2009)
Rosa et al. (2007)
Sharma et al. (2012)
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Table 3. TDF domains, themes of determinants and examples of determinants (barriers and facilitators)
TDF domain (no. of
studies reporting the
domain) Themes




resources (n = 36)
Side effects of medicationa • Experience of actual side effects such as
sedation, weight gain, sexual dysfunction,
fatigue, cognitive impairment,
extra-pyramidal and hormonal side effects
Medication formulation and
treatment regimen
• Number and frequency of prescribed
medication regimen with more complex/
demanding regimens being negatively
associated with adherence
• Long-acting injections had higher
adherence than oral medications
Ineffective medicationsa • Medication not working or worsening
symptoms after taking medication
Cost of medication • Too expensive or inability to pay • Free medication
Irregular routinea • Irregular daily routine or work schedule
Access to health care
providers
• Poor access to mental health service
including unavailability of doctors,









• Belief they ‘did not need’medications for BD
• ‘Felt well, saw no need to take medication’
• ‘If there are no symptoms, why take
medications’
Belief about the positive or
negative effects of
medicationsa
• Felt less creative, less productive, less of
myself, ‘missing highs’
• Concern about side effects
• Not wanting to be sick, to keep mood
stable and functioning
• The high belief that treatment would be
helpful
Doubt about the effectiveness
of medication
• Belief that medication does not work
Belief that it is unnatural to
take psychotropic
medications
• Belief that it is unhealthy and unnatural to
take medication to keep mood stable
To avoid punishment/trouble • Belief that they will be sectioned or
hospitalised if they did not take their
medication
Knowledge (n = 23) Knowledge about BD and its
treatmenta
• A lack of knowledge and awareness about
the course of illness and treatment
• Majority of the non-compliant patients
were not aware that the Lithium stabilises
the mood
• Not knowing the need to take medication
regularly
• Not knowing that medications should be
continued even when free of symptoms
• Better insight into illness
• A high coherent understanding of their
disorder
• Being sufficiently informed about the
disorder and its treatment
• ‘My mental health care provider team
made me aware of what to expect from
good bipolar disorder care’
Understanding how and when
to take medication
• Unclear about prescription directions
• Misunderstanding prescription directions
Social influences
(n = 19)
Personal support by the care
provider
• ‘My mental health care provider team
makes sure that we stay in regular contact’
• ‘I feel understood by my mental health
care provider team’
Feeling stigma • The more self-stigmatised the patients
were the lower their adherence
• Ironically, as though the mental illness was
not associated with enough stigma, the
decision to cease medication, even when
experienced as an important part of one’s
personal recovery, was stigmatising in its
own right, leading them to conceal their
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Table 3. (Continued.)
TDF domain (no. of
studies reporting the
domain) Themes
Examples of determinants of medication adherence
Barriers Facilitators
Support or opposition from
family, friends, relatives to
diagnosis and treatmenta
• Family and friends discouraging from
taking medication
• ‘My mother said I should think about it and
try to use … reason and creativity instead
of the medication’
• Having someone to support medication
taking, monitoring symptoms, etc.
• ‘I used medication to please my parents,




Forgetfulness/carelessness • Forgetting or not remembering to take the
medication as prescribed
• Laziness or careless at times about taking
medications
• Individuals had a variety of methods to
help them remember to take
medications, including putting them in a
consistent/specific place, labelling or
writing reminders, taking medications at
a consistent/specific time
Medication taking routine • Difficulties in maintaining pill-taking
routines
· Attaching medication taking to other
routine behaviours (e.g. taking medication
after cleaning teeth)
Emotion (n = 12) Fear of addiction or side
effect of medication
• Worried about being dependent on
medications
• Fear of side effects of medications
Feeling threatened • The threat of hospitalisation if
medication is not taken
Feeling of not being able to
fulfil a social role
• Could not take care of my kids while on
medication because I did not have the





• Negative experience of how the medication
was prescribed or administered
• Taking medication every day is a frustration
• Bothered that mood was controlled by
medication
Intentions (n = 12) Denial of illness or illness
severity
• Among reasons for non-adherence, denial
of illness was the most commonly
specified. With higher denial, adherence
decreased exponentially
• Adherent patients tended to accept that
they are ill
Acceptance or denial of the
need for treatment
• More than half of non-compliant patients
expressed that they do not accept lithium
treatment for a long time and as a normal
routine
• From the compliant patients, there was
100% of acceptance of Lithium
treatment
Intentional non-adherence • Not wanting to take medication





Listening and shared decision
makinga
• Absence of shared decision making was
believed to result in non-adherence and
high rates of re-admission to hospitals
• ‘I feel that my health care practitioner




• Better patient-physician relationship
• Satisfied with the competence of the
doctor
Being in control of the
treatment regime
• Wanted to self-adjust the dose
• Using regularly prescribed medication as
‘standby drugs’ to stop mania
Belief about
capabilities (n = 6)
Belief in self and controla • I think it’s like any other condition … the
more autonomy you give the patient …
the more likely they are to comply
Conflicting belief between
clinician and patient
• Some research participants reported that
clinicians interpreted their valued personal
strengths and self-assessed health
resources as part of psychopathology.
Unsurprisingly, this led to non-adherence
(Continued )
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cost of medication, etc. This finding accords with previous studies
(Garcia et al., 2016; Kikkert et al., 2006; Salzmann-Erikson &
Sjodin, 2018; Velligan et al., 2009). Side effects were represented
in the domains of both ‘Environmental context and resources’
and ‘Beliefs about consequences’. This was because patients
reported non-adherence arising from both experiencing side
effects and being concerned that side effects may result from tak-
ing the medication. Each requires a different BCT, for example,
the former may be better addressed by ‘restructuring the physical
environment,’ e.g. by changing medication with a lower
propensity of a particular side effect that the patient is experien-
cing. In contrast, the latter aligns with BCTs such as ‘pros and
cons,’ e.g. discussing the risk and benefit of taking and not taking
the medication (The UCL Centre for Behaviour Change, 2019).
The dominance of ‘Beliefs about consequences’ on medication
adherence in this review is supported by other studies using the
TDF (Crayton et al., 2017; Easthall et al., 2019). Belief about
the necessity or concerns of medication were frequently reported
determinants of adherence within this domain. As often reported
in clinical practice, many people stop taking their medication
Table 3. (Continued.)
TDF domain (no. of
studies reporting the
domain) Themes
Examples of determinants of medication adherence
Barriers Facilitators
Goals (n = 3) Different priorities over
medication taking
• Psychiatric medications interfered with the
things that give life meaning and purpose
• Relief from personal stress was more
important than taking medications
Desire to experience manic
symptoms
• Stopping medication to experience mania
Skills (n = 2) Provision of training to
manage BD
• ‘My mental health care provider team
has provided training in what I need to
do to carry out good bipolar disorder
care’
Optimism (n = 0) No determinants mapped to this domain
Reinforcement (n = 0) No determinants mapped to this domain
Behavioural
regulation (n = 0)
No determinants mapped to this domain
aClinicians only reported these themes of determinants.
Fig. 2. Comparison of TDF domains reported by patients and clinicians. No. of patients only studies = 50; no. of clinicians only studies = 2; no. of studies including
patients and clinicians = 3. Two studies exploring researchers’ perspectives were not included in this graph.
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once they feel better believing they no longer need them. On the
contrary, some people believe they do not need medication at the
start of the treatment and thus do not initiate them. Therefore,
BCTs such as ‘pros and cons’ may play a vital role in medication
adherence (The UCL Centre for Behaviour Change, 2019).
The absence of determinants mapped to the TDF domains
‘Optimism’, ‘Reinforcement’ and ‘Behavioural regulation’ does
not necessarily mean that these three domains are unimportant
to medication adherence in BD. Previous studies may not have
explored these specific domains. Some adherence intervention
studies suggest ‘Reinforcement’ using financial incentives may
improve adherence (Priebe, Bremner, Lauber, Henderson, &
Burns, 2016). Similarly, optimism, as measured by the revised
Life Orientation Test (Herzberg, Glaesmer, & Hoyer, 2006), was
reported to lead to improved adherence in acute coronary syn-
drome (Millstein et al., 2016). Revised Life Orientation Test
includes statements such as ‘Overall, I expect more good things
happen to me than bad’, ‘In uncertain times, I usually expect
the best’ (Herzberg et al., 2006). However, these may not be modi-
fiable. Future study should explicitly investigate the extent to
which these unrepresented domains are relevant to non-
adherence in this population and whether they are modifiable
in the context of medication adherence.
Although there was a significant overlap between determinants
reported by clinicians and patients, there were also notable
distinctions. These distinctions may explain the limited progress
made by clinicians in identifying and addressing non-adherence
(Hartung et al., 2017; Nieuwlaat et al., 2014). However, these
distinctions may also have arisen due to the small number of
studies exploring the clinician’s perspective.
Clinician reported determinants mapped to less than half of the
TDF domains, suggesting that clinicians may not be aware of the
broad range of determinants affecting medication adherence or
studies were not designed to elicit this information from clinicians.
The influence of negative emotion evoked by taking medication and
intentional non-adherence was the most notable omission from
clinicians’ perspectives. This incomplete picturemay result in adher-
ence support poorly reflecting patients’ needs (Brown et al., 2017).
This is evident from current adherence support being focused on
a very limited number of determinants (MacDonald, 2017;
National Institute of Healthand Care Excellence (NICE), 2009;
Thompson, Kulkarni, & Sergejew, 2000; Torres-Robles et al. 2018).
Strengths and limitations
This study offers three novel aspects in the field of medication
adherence research in BD. Firstly, the study focuses on potential
adherence intervention targets by reporting only modifiable
determinants. Secondly, as the application of theory is a core
requirement for developing and implementing complex interven-
tions, our use of a theoretical framework provides the foundations
for developing future medication adherence interventions and
their implementation. Finally, the comprehensive nature of a the-
oretical framework rather than an individual theory has enabled
us to identify gaps in the literature.
Using the TDF as an a priori framework to organise modifi-
able determinants is a deductive approach. However, we did not
constrain extraction of the determinants and mapping them to
only the TDF domains as any determinants not aligned to the
TDF would have been captured in the ‘Others’ category. The
lack of detailed description of the determinants in some studies
risked mapping them to incorrect TDF domains. For example,
some studies described ‘hassle to acquire medication’ as a deter-
minant of adherence. It could mean the patient has difficulty
obtaining medication due to not knowing how to order their pre-
scription or difficulty remembering to order a prescription or lack
of transport/money/time to order prescription. Each interpret-
ation would be mapped to a different TDF domain. Further quali-
tative study with patients will facilitate these further refinements
in mapping.
We presented the modifiable determinants of adherence iden-
tified from a wide range of study designs. We recognise that the
medium via which data are collected can influence the range of
determinants captured. For example, interviews may elicit a
greater range of determinants that are personal to the individual
v. a structured survey of potentially relevant determinants
(Lagard, Keegan, & Ward, 2003). This non-restrictive approach
has contributed to identifying a list of modifiable determinants
as comprehensively as possible which was one of the goals of
this study.
Implications for practice
We provide theory and evidence-based modifiable determinants
that influence a patient’s ability to adhere to their prescribed medi-
cation. All these determinants should, therefore, be considered and
potentially discussed with patients when initiating treatment and at
every review. Currently, clinicians may not be providing adherence
support tailored to patients’ wide-ranging needs.
Implications for research
The application of a theoretical framework to the systematic
review has enabled us to identify gaps in the literature where
researchers have not sought to investigate the relevance of facili-
tators of adherence. Further research to explicitly capture the
facilitators of adherence may help design future adherence inter-
ventions. The existing literature mostly represents the patient
voice; absence of the carer voice is a notable gap given their
role in supporting medication adherence in people with mental
health problems (Deane, McAlpine, Byrne, Davis, & Mortimer,
2018). Future research exploring carers’ views on modifiable
determinants of medication adherence in BD is, therefore, needed.
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